Frankfurt: AstraZeneca executive said the prospect offered new treatment to prevent Covid-19 able to position British drug makers as suppliers of vaccines and drugs that maintain infectious diseases.
Statement by the executive of Mene Pangalos on Friday, after the AZD7442 antibody drug was proven to prevent Covid-19 in the trial, came after another leading executive, Ruud Dobber, said last month that different options were being explored for vaccine operations, which came from.
Collaboration with Oxford University.
“When we talk about the decision around the vaccine we say clearly we want to see what the results are 7442 too,” Pangalos told Reuters.
“There are no other companies that provide two molecules against SARS-COV2.
This must help us in positioning us in terms of Covid,” he added.
SARS-COV2 is a scientific name for Covid-19 virus which causes a virus.